Key Notes
- Claude agents in Anthropic's new life sciences lab autonomously discovered a novel enzyme system called ART, found in bacteriophage DNA and sharing structural features with CRISPR, after roughly 950 agents spent 21 hours searching a database of over 200,000 reverse transcriptases.
- One agent noticed an unusual tandem repeat pattern next to a reverse transcriptase gene, analyzed it, and filed a report that human scientists confirmed as a genuinely new biological system whose function remains under investigation.
- CRISPR pioneer Feng Zhang called the finding genuinely intriguing after reviewing Anthropic's pre-print, and the announcement follows Anthropic's separate disclosure last week of a physical biology lab focused on AI assisted drug discovery.
Anthropic said Claude agents in its new life sciences lab have autonomously discovered a previously uncharacterized enzyme system in bacteriophage DNA, one that shares structural features with CRISPR, the gene editing technology that transformed biotechnology after it was first noticed as an odd repeat pattern in bacterial DNA decades ago.
An AI Agent Spots A Pattern No One Had Named
According to Anthropic’s announcement, the company assigned Claude agents to search a large database of DNA sequences for interesting, uncharacterized examples of reverse transcriptases, enzymes that copy RNA into DNA.
Roughly 950 agents spent 21 hours combing through the data using 210 million tokens, gathering more than 200,000 known reverse transcriptases, narrowing them to 3,500 new candidate systems, and eventually producing detailed reports on the 20 most compelling candidates.
During that process, one agent noticed an unusual reverse transcriptase family and examined the raw DNA sequence near it in closer detail. According to Anthropic, the agent wrote that the DNA next to the enzyme was spectacular, describing what it could see by eye as a tandem repeat array resembling something CRISPR like. It then proceeded to count the repeats, measure their spacing, compare the layout against known systems, and search the literature for any prior description of the pattern, ultimately filing a report for human review.
A System Called ART
Anthropic’s scientists confirmed the pattern marked a genuinely new biological system, which they have named array associated reverse transcriptases, or ART. The system consists of the reverse transcriptase itself, a neighboring gene of unknown function, and a long array of evenly spaced DNA repeat sequences, found mainly in bacteriophages, the viruses that infect bacteria.
Early laboratory experiments show the ART array is also expressed as a set of distinct short RNA molecules, suggesting it may function in a way loosely analogous to CRISPR systems, though Anthropic said the actual biological function of ART remains unknown and further experiments are underway.
Feng Zhang, a pioneer of CRISPR genome editing at MIT and the Broad Institute, reviewed Anthropic’s pre-print and called the identification of RNA repeat arrays associated with reverse transcriptases genuinely intriguing and worth further investigation, adding that he hopes the work encourages more scientists to explore how AI can support their own research.
A New Lab Built Around Human Scientists and Claude
The discovery comes from a life sciences research group and laboratory Anthropic formed in the spring of 2026 to test whether general AI models can help systematize and accelerate biological discovery.
The lab is staffed entirely by human scientists who previously worked on understanding the evolution and regulation of CRISPR systems and discovering enzymes for cell and gene therapies, and Anthropic said all physical lab work is performed by people, with Claude used to help design experiments, search literature, and interpret results rather than to handle equipment directly.
According to Anthropic, its involvement in the ART discovery was limited to giving Claude an initial prompt to search for interesting reverse transcriptase examples and then carrying out the physical lab work once a candidate was identified, while Claude agents independently investigated distinct enzyme families and used their own judgment to flag which candidates were worth a closer look.
The lab operates only at the lower biosafety levels, BSL-1 and BSL-2, and Anthropic said it does not handle pathogens capable of infecting humans.
Part Of A Broader Anthropic Push Into Biology
The enzyme discovery follows Anthropic’s confirmation last week that it operates a separate physical biology lab focused on AI assisted drug discovery, underscoring a wider effort by the company to expand into life sciences applications even as it continues to face broader questions about the pace and safety of frontier AI development.
Notably, the ART announcement landed on the same day OpenAI and Anthropic’s own chief executives addressed the United Nations Security Council about AI risk, and hours after Australia’s prime minister revealed an OpenAI agent had breached a government Medicare portal, an unrelated but coincidental convergence of stories that captures how unevenly AI’s capabilities and its risks are currently being demonstrated.
Anthropic said it released a pre-print detailing the ART discovery and is inviting other scientists to propose research questions the lab’s Claude driven workflow could be applied to, though the company did not provide a timeline for determining ART’s actual biological function or say how many other candidate systems from the same search remain under active investigation.
Disclaimer: AIstify is an independent media brand owned and operated by NuvexMedia LLC, publishing news, research, and insights on artificial intelligence, emerging technologies, automation, and related industries. NuvexMedia LLC invests in and collaborates with companies across the AI, technology, software, and digital innovation sectors. These relationships do not influence AIstify’s editorial coverage, and the publication maintains full editorial independence to provide accurate, timely, and objective information. © 2026 NuvexMedia LLC. All rights reserved. This content is for informational purposes only and should not be considered legal, tax, investment, financial, or other professional advice.
